These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34696358)

  • 21. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.
    Gowda P; Patrick S; Joshi SD; Kumawat RK; Sen E
    Cytokine; 2021 Jun; 142():155496. PubMed ID: 33773396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms.
    Paiardi G; Richter S; Oreste P; Urbinati C; Rusnati M; Wade RC
    J Biol Chem; 2022 Feb; 298(2):101507. PubMed ID: 34929169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 25. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
    Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
    F1000Res; 2020; 9():576. PubMed ID: 32802318
    [No Abstract]   [Full Text] [Related]  

  • 27. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress.
    Chen D; Zheng Q; Sun L; Ji M; Li Y; Deng H; Zhang H
    Dev Cell; 2021 Dec; 56(23):3250-3263.e5. PubMed ID: 34706264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex.
    Bhattacharya M; Sharma AR; Mallick B; Sharma G; Lee SS; Chakraborty C
    Infect Genet Evol; 2020 Nov; 85():104587. PubMed ID: 33039603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein.
    Staufer O; Gupta K; Hernandez Bücher JE; Kohler F; Sigl C; Singh G; Vasileiou K; Yagüe Relimpio A; Macher M; Fabritz S; Dietz H; Cavalcanti Adam EA; Schaffitzel C; Ruggieri A; Platzman I; Berger I; Spatz JP
    Nat Commun; 2022 Feb; 13(1):868. PubMed ID: 35165285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
    Barnes CO; Jette CA; Abernathy ME; Dam KA; Esswein SR; Gristick HB; Malyutin AG; Sharaf NG; Huey-Tubman KE; Lee YE; Robbiani DF; Nussenzweig MC; West AP; Bjorkman PJ
    Nature; 2020 Dec; 588(7839):682-687. PubMed ID: 33045718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.
    Lusvarghi S; Wang W; Herrup R; Neerukonda SN; Vassell R; Bentley L; Eakin AE; Erlandson KJ; Weiss CD
    J Virol; 2022 Jan; 96(1):e0111021. PubMed ID: 34668774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway.
    Xu H; Akinyemi IA; Chitre SA; Loeb JC; Lednicky JA; McIntosh MT; Bhaduri-McIntosh S
    Virology; 2022 Mar; 568():13-22. PubMed ID: 35066302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
    Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
    Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
    Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites.
    Lechuga GC; Souza-Silva F; Sacramento CQ; Trugilho MRO; Valente RH; Napoleão-Pêgo P; Dias SSG; Fintelman-Rodrigues N; Temerozo JR; Carels N; Alves CR; Pereira MCS; Provance DW; Souza TML; De-Simone SG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
    Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
    Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.